Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles - PubMed (original) (raw)

Clinical Trial

. 1995 Jul-Aug;19(4):565-9.

doi: 10.1007/BF00294724.

Affiliations

• PMID: 7676701
• DOI: 10.1007/BF00294724

Clinical Trial

Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles

T Takahashi et al. World J Surg. 1995 Jul-Aug.

Abstract

A novel method of prophylaxis and treatment for peritoneal carcinomatosis--mitomycin C bound to activated carbon particles (MMC-CH)--was tested in patients with advanced gastric cancer in a prospective randomized study. Activated carbon particles are taken up selectively by lymphatic tissues, which seem to be a primary site of peritoneal carcinomatosis in the peritoneal cavity, and adsorb a large amount of anticancer agent mitomycin C, which is subsequently released slowly and for a protracted period. A group of 113 patients who underwent radical resection for gastric cancer with definite serosal involvement were entered in this trial. Those in the control group received no intraperitoneal anticancer drugs. Patients in the MMC-CH group were given 50 mg mitomycin C as MMC-CH, which was dispersed throughout the peritoneal cavity just before surgical closure. No other anticancer drugs were given to these patients after surgery. The 2- and 3-year survival rates for the MMC-CH group were 42% and 38%, respectively; and the rates for the control group were 28% and 20%, respectively. The difference in survival between the two groups was significant at 2 and 3 years (p < 0.05). For the survival of patients with macroscopic peritoneal carcinomatosis, there was no difference between these two groups. For the survival of patients who underwent histologically curative resection, 2- and 3-year survivals for the MMC-CH group were 66% and 66%, respectively and for the control group 35% and 20%, respectively. The difference between the two groups was statistically significant (p < 0.01) at both 2 and 3 years.(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

Similar articles

• [Intraoperative chemotherapy with intraperitoneal activated carbon particles adsorbing mitomycin C against peritoneal dissemination of gastric cancer].
  Iwamoto A, Takahashi T, Sasabe T, Itoh M, Kondoh S, Seiki K, Yoneyama C, Shimotsuma M, Hagiwara A, Yamaguchi T, et al. Iwamoto A, et al. Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 2):2748-51. Gan To Kagaku Ryoho. 1989. PMID: 2506820 Japanese.
• [The prevention of peritoneal dissemination of gastric cancer with intraperitoneal activated carbon particles absorbing mitomycin C].
  Ohgaki M, Imanishi T, Ohyama T, Tsujimoto H, Ozaki K, Chohei S, Shimotsuma M, Hagiwara A, Takahashi T. Ohgaki M, et al. Gan To Kagaku Ryoho. 1994 Sep;21(13):2320-2. Gan To Kagaku Ryoho. 1994. PMID: 7944469 Clinical Trial. Japanese.
• [Targeting chemotherapy with activated carbon particles adsorbing anti-cancer drugs].
  Hagiwara A, Takahashi T, Kondoh S, Iwamoto A, Sawai K. Hagiwara A, et al. Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-1):1038-42. Gan To Kagaku Ryoho. 1988. PMID: 2455477 Review. Japanese.
• [Prophylaxis and treatment of peritoneal metastasis from gastric cancer].
  Kaibara N. Kaibara N. Nihon Geka Gakkai Zasshi. 1996 Apr;97(4):308-11. Nihon Geka Gakkai Zasshi. 1996. PMID: 8692149 Review. Japanese.

Cited by

• Preliminary results of the use of intraperitoneal carbon-adsorbed mitomycin C in intra-abdominal malignancy.
  Ubhi SS, McCulloch P, Veitch PS. Ubhi SS, et al. Br J Cancer. 1997;76(12):1667-9. doi: 10.1038/bjc.1997.615. Br J Cancer. 1997. PMID: 9413960 Free PMC article.
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.
  Seshadri RA, Glehen O. Seshadri RA, et al. World J Gastroenterol. 2016 Jan 21;22(3):1114-30. doi: 10.3748/wjg.v22.i3.1114. World J Gastroenterol. 2016. PMID: 26811651 Free PMC article. Review.
• Endoscopic ultrasonography in the preoperative staging of gastric cancer: accuracy and impact on surgical therapy.
  Willis S, Truong S, Gribnitz S, Fass J, Schumpelick V. Willis S, et al. Surg Endosc. 2000 Oct;14(10):951-4. doi: 10.1007/s004640010040. Surg Endosc. 2000. PMID: 11080410 Clinical Trial.
• Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time?
  Feingold PL, Kwong ML, Sabesan A, Sorber R, Rudloff U. Feingold PL, et al. J Gastrointest Oncol. 2016 Feb;7(1):87-98. doi: 10.3978/j.issn.2078-6891.2015.098. J Gastrointest Oncol. 2016. PMID: 26941987 Free PMC article. Review.
• Meta-analysis of intraperitoneal chemotherapy for gastric cancer.
  Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR. Xu DZ, et al. World J Gastroenterol. 2004 Sep 15;10(18):2727-30. doi: 10.3748/wjg.v10.i18.2727. World J Gastroenterol. 2004. PMID: 15309728 Free PMC article.

References

1. 1. Anticancer Res. 1987 Mar-Apr;7(2):167-70 - PubMed
2. 1. Surgery. 1988 Nov;104(5):874-81 - PubMed
3. 1. Gan. 1980 Aug;71(4):578-9 - PubMed
4. 1. Cancer Res. 1973 Dec;33(12):3181-8 - PubMed
5. 1. Cancer Res. 1993 Feb 1;53(3):687-92 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Medical

  • MedlinePlus Health Information